Pipeline

ProductsClinical
indication
RegionLicensee
Ripasudil hydrochloride hydrateGLANATEC®Glaucoma and ocular hypertensionJapan, AsiaKowa
K-321Fuchs endothelial corneal dystrophyUS, etc.Kowa
Ripasudil hydrochloride hydrate/ Brimonidine tartrateGLA-ALPHA®Glaucoma and ocular hypertensionJapanKowa
DW-1002ILM stainingEurope, US, etc.DORC
ILM stainingJapanWakamoto Pharmaceutical
ALC stainingJapan
ILM, ERM and PVR membrane stainingEurope, etc.DORC
ILM staining and ERM stainingUSDORC
DW-1001Ophthalmic treatment agentJapanROHTO Pharmaceutical
H-1337Glaucoma and ocular hypertensionUSDeveloped internally
DW-5LBTNeuropathic pain after shinglesUSJointly developed with MEDRx
DWR-2206Bullous KeratopathyJapanJointly developed with ActualEyes
Treatment for
retinopathy of prematurity
Retinopathy of prematurityJapanDeveloped by subsidiary JIT

R&D Projects for new drug discovery

ProductsClinical indicationDevelopment processPartner
Signal transduction inhibitor developing projectsOphthalmology,Central Nervous System,Cardiovascular System,Respiratory SystemFundamental Research Mie Univ. etc.
New device developing projectsGlaucoma,Corneal disorders,Retinal diseasesFundamental Research Glaukos